Grifols, ES0171996087

Grifols stock heads into the open after a 1.55 percent gain

Published on 09/22/2026 at 05:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 18, 2026, Grifols stock stood at EUR 9.71 after adding 1.55 percent. The Spanish listing was quoted in a session shaped by a new company update on Alzheimer disease research.

Isometrische 3D-Grafik der Plasma-Wertschöpfungskette von Spende bis Medikament
Isometrische 3D-Illustration zeigt die Wertschöpfungskette von der Plasmaspende bis zum Medikament bei Grifols S.A. ES0171996087, Illustration mit AI erstellt.

Grifols stock closed at EUR 9.71 on the BME on September 18, 2026, gaining 1.55 percent. The move followed a session in which the shares added EUR 0.15 from the prior close, according to the dated Spanish-market snapshot.

September 18, 2026 in numbers

Grifols S.A. (ISIN ES0171996087, BME: GRF) was quoted at EUR 9.71 on September 18, 2026, compared with EUR 9.56 previously. The available session data place the daily change at plus 1.55 percent and provide the closing value for the Spanish listing.

As Grifols announced on September 21, 2026, new real-world evidence from the AMBAR program will be presented at the Annual Meeting of the Spanish Society of Neurology in Seville from November 17 to November 21, 2026.

Company update for today

The company update remains the latest dated corporate item heading into the September 22, 2026 session. The AMBAR findings cited by Grifols include a 61 percent reduction in disease progression among patients with mild to moderate Alzheimer disease compared with untreated patients.

The broader market backdrop included a 1.5 percent gain for the S&P 500 on September 21, 2026, while the Nasdaq Composite rose 2.3 percent. Those US index figures provide a separate market reference from Grifols home-market close.

Disclaimer...

en | ES0171996087 | GRIFOLS | boerse | 70149908 | bgmi